Calvin I’m not trying to be carrier of bad news
it’s just last 3 years has me contemplating
various scenarios.
I still cannot get a logical answer to valuations
on E4 . Over $1/2 billion. Then we have milestone payments. This is all after buying
The Product. Bloody Hell that a Lot of Money
Definitely multiples of Rest of World Combined
Where is Justification Here?
Other Countries even have extra product
rights.
Should we place similar valuations on their
other Women’s Health Pre - Menopause
and Menopause Osteo. What 10% each.
Where does this leave us ??????
Ann: 2019 AGM CEO's Speech, page-115
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |